Tens of billions of "unspeakable" market: in pharmacies to sell, gross profit of more than 88%, 171 products in line

The 10 billion anti-ED (erectile dysfunction) market is ushering in new entrants

Once approved, MED3000 will be the first over-the-counter drug (OTC)

According to media reports, MED3000 is a transdermal gel formulation of nitroglycerin that does not require oral administration and can take effect in 10 minutes, significantly faster than tadalafil (30 to 60 minutes).

"The current anti-ED drugs are prescription drugs, some drugs have a relatively large toxic side effect, before taking the drug needs to diagnose whether the patient has a related disease, such as the patient has a myocardial infarction, cerebral hemorrhage, etc.

"Although most of the current anti-ED drugs are prescription drugs, patients can buy from Internet hospitals, so for patients, in terms of purchase, there is little

Competition is fierce, and there are 171 "Viagras" in line

ED is commonly known as "impotence", the media quoted the national health and health survey data said that the overall prevalence of male ED in China is 40.

According to WHO research, andrology diseases are increasing at a rate of 3% per year, and men's physiological health problems have gradually developed into a global health problem

Phosphodiesterase 5 (PED-5) inhibitors are first-line anti-ED treatments, mainly including sildenafil, valdenafil, and tadalafil

As the "big brother" of Sildenafil, Pfizer's original research drug "Viagra" (commonly known as "Viagra") once became synonymous with

In 2003, the Tataraf (trade name: Xi'aali) developed by Eli Lilly in the United States and the vatarafil (trade name: Arita) developed by Bayer in Germany were also introduced

The huge gold absorption capacity has naturally attracted the attention

At present, the anti-ED drug market has quite a large number of players and fierce competition

Sildenafil has been approved for sildenafil tablets and sildenafil citrate oral tablets

There are as many as 21 companies with Tadalafi production approvals; Valdinafil is relatively rare, with only one Coron Pharmaceuticals

In addition to approved products, according to Intranet data, there are still 171 clinical trials underway, of which tadalafil has 108, sildenafil has 54, and valdenafil has 9
.

"Although the current anti-ED drug market belongs to a two-point pattern, foreign pharmaceutical companies dominate, and domestic pharmaceutical companies have a large market share such as Baiyun Mountain, but anti-ED drugs are still profitable
.
" Its production costs are very low, and some companies have only tens of millions of sales, but their profits are very high
.
Shi Lichen told Times Finance
.

According to the financial report data, in 2021, Baiyun Mountain's Jinge sold 98.
4982 million pieces, achieving revenue of 988 million yuan, an increase of 18.
73% year-on-year, and the gross profit margin ranked first among all products, as high as 88.
60%.

According to intranet data, in 2019, Jingo's sales have surpassed the "WanAisk" of Pfizer's original research and become the first anti-ED drug
sold in China.
In 2021, the terminal sales of anti-ED drugs in pharmacies nationwide have exceeded 3.
6 billion yuan, with a sales growth rate of 9.
02%, of which Jinge's sales accounted for 40.
63%, ranking leading
in sales.
In addition, in 2021, the largest sales of sildenafil citrate is 50mg, and jingo accounts for 82.
72%
of sales in the 50mg specification.

According to the financial report of Kelun Pharmaceutical, in the first half of this year, the company's sales revenue of valdenafil hydrochloride tablets increased by 62.
59%
year-on-year.

"Now the domestic elderly population is increasing, and anti-ED drugs are basically available to people under the age of 70, so the overall market demand will also increase
.
" Shi Lichen told Times Finance
.

Tens of billions of market, how to break through?

The unspeakable problem of ED is spawning a ten-billion-dollar market
.

According to the data of Guanyan Tianxia Research Report, the market size of the domestic anti-ED drug industry from 2015 to 2020 was 2.
43 billion yuan, 2.
76 billion yuan, 3.
14 billion yuan, 3.
65 billion yuan, 4.
28 billion yuan and 5.
35 billion yuan, and the market size is expected to reach 9.
88 billion yuan
in 2024.

Under the "temptation" of nearly 10 billion markets, more and more companies have entered the track and competed fiercely
.

However, most of the currently approved PED5 inhibitors are tablet products
.

Shi Lichen pointed out that most of the current PED5 inhibitors are tablets, and most of the raw materials of these tablets are similar and there is a certain homogenization
.

Taking tadalafil as an example, data from the State Drug Administration shows that of the 21 tadalafil products that have been approved, only 1 is a mouth-soluble film dosage form, and the manufacturer is Qilu Pharmaceutical
.

Times Finance asked the official flagship store customer service of Qilu Pharmaceutical Taobao as a consumer, which said, "The company's Shendu Tadala non-oral coating film does not need water when taking it, the drug film can be quickly dispersed and dissolved in the mouth, it is more convenient to take, which can alleviate the tension and anxiety that patients may produce when taking drugs to a certain extent, in addition, the oral coating film tastes good and has obvious breath freshness effect
.
" ”

The customer service staff also stressed that the effect of oral-coated film products and tablet products is the same
.

Judging from the current clinical trial declarations, relevant companies are differentiating
anti-ED drugs.

According to the data of The Intranet, there are 9 clinical trials of tadala non oral instant film agent/oral dissolved film agent that have been declared; Sildenafil is more numerous, with 17 clinical trials of oral disintegration tablets already declared, while 1 clinical trial is underway on oral lysate membranes and oral suspensions
.

In terms of anti-ED innovative drugs, domestic pharmaceutical companies are also accelerating
.
In January this year, Yuekang Pharmaceutical announced that its self-developed anti-ED drug adenafil citrate tablets (trade name: Alex) was officially listed, which is the first domestic patented new drug
in the field of class 1.
1 anti-ED in China.

"Not only the way of taking drugs, but also the effect of use and the price of drugs are also important factors
affecting the competition of anti-ED drugs.
If a new anti-ED drug can surpass existing drugs in these three indicators, then its competitive advantage will be more obvious
.
Shi Lichen said
.